English 中文

 : +855-9285-1658  : [email protected]

www.kingken.com

All Categories

  • Hepatitis
  • Diabetes
  • Lung
  • Colorectal
  • Lymphoma
  • Leukemia
  • Breast
  • Kidney
  • Thyroid
  • Myeloma
  • Stromal
  • Stomach
  • Liver
  • Melanoma
  • Immune
  • Others
  •  Home
  •  About Us
  •  Diseases
  •  News
  •  Verify
  •  Order
  •  Contact
Hepatitis
  2017-04-20 10:47

FDA approves Gilead's first all genotypic hepatitis C new drug Epclusa

June 29, 2016 - Gilead, a ubiquitous genotypic hepatitis C cocktail therapy in the field of hepatitis C, has made a major milestone in the US regulation, Epclusa. FDA has approved Epclusa for the treatment of all 6 genotypes of hepatitis C.
  2017-04-20 20:58

Hepatitis C new drug Epclusa was approved by the United States and the European Union

July 9, 2016 - the ubiquitous gene type hepatitis C cocktail therapy (Epclusa) developed by Gilead, the absolute hegemon in the field of hepatitis C, has achieved a major milestone in the United States
  • Navigation
  • Hepatitis
  • Diabetes
  • Lung
  • Colorectal
  • Lymphoma
  • Leukemia
  • Breast
  • Kidney
  • Thyroid
  • Myeloma
  • Stromal
  • Stomach
  • Liver
  • Melanoma
  • Immune
  • Others
  • Total 1 Page/2 Record
    • Email[email protected]
    • Phone+855-9285-1658
    • AddressHouse No.11A St. 348 Borey Vimean Phnom Peng, Road 598, Sangkat Toul Sangke, Khan Russey Keo, Phnom Penh-12105, Cambodia.
    • Websitewww.kingken.com

    Copyright © 2020 KINGKEN (CAMBODIA) PHARMACEUTICALS CO., LTD.